secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001789769-25-000079
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio Q2 net loss $3.24/share; cash $103.6M; IND cleared for '2510
-----------------------------------------------------------------------

- Cash, equivalents, marketable securities and long-term investments of $103.6M as of June 30, 2025; funded beyond 2026.
- Net loss per share $3.24 (GAAP) and $2.88 (non-GAAP) for Q2 2025, vs $2.29 and $1.57 year-ago.
- R&D expenses $6.7M in Q2 2025; in-process R&D expenses $10.0M; G&A expenses $6.2M.
- U.S. IND for AXN-2510/IMM2510 cleared; U.S. trial initiation expected before end of 2025.
- Appointed Jamie Freedman, M.D., Ph.D. as Chief Medical Officer in June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000079/0001789769-25-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000079/til-20250813.htm
  HTML page:      https://secwatch.observer/filing/0001789769-25-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer